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support for smoking cessation
Abstract
Objectives. To evaluate the uptake and effectiveness of tailored smoking cessation support, provided primarily
by the practice nurse (PN), and compare this to other forms of cessation support. Methods. Three arm cluster
randomized controlled trial conducted in 101 general practices in Sydney and Melbourne involving 2390
smokers. The Quit with PN intervention was compared to Quitline referral and a usual care control group.
Smoking cessation pharmacotherapy was recommended to all groups. Outcomes were assessed by self-report
at 3- and 12-month follow-up. Uptake of the interventions is also reported. Results. The three groups were
similar at baseline. Follow-up at 12 months was 82%. The sustained and point prevalence abstinence rates,
respectively, at 3 months by group were: PN intervention 13.1% and 16.3%; Quitline referral 10.8% and
14.2%; Usual GP care 11.4% and 15.0%. At 12 months, the rates were: PN intervention 5.4% and 17.1%;
Quitline referral 4.4% and 18.8%; Usual GP care 2.9% and 16.4%. Only 43% of patients in the PN
intervention group attended to see the nurse. Multilevel regression analysis showed no effect of the
intervention overall, but patients who received partial or complete PN support were more likely to report
sustained abstinence [partial support odds ratio (OR) 2.27; complete support OR 5.34]. Conclusion. The
results show no difference by group on intention to treat analysis. Those patients who received more intensive
PN intervention were more likely to quit. This may have been related to patient motivation or an effect of PN
led cessation support.
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To evaluate the uptake and effectiveness of tailored smoking cessation support, provided 
primarily by the practice nurse (PN), and compare this to other forms of cessation support.    
 
Methods 
Three arm cluster randomised controlled trial conducted in 101 general practices in Sydney and 
Melbourne involving 2390 smokers.  The Quit with PN intervention was compared to Quitline 
referral and a usual care control group. Smoking cessation pharmacotherapy was recommended 
to all groups. Outcomes were assessed by self-report at three month and 12 month follow up. 
Uptake of the interventions is also reported. 
 
Results 
The three groups were similar at baseline. Follow-up at 12 months was 82%. The sustained and 
point prevalence abstinence rates respectively at three months by group were: PN intervention 
13.1% and 16.3%; Quitline referral 10.8% and 14.2%; Usual GP care 11.4% and 15.0%. At 12 
months the rates were: PN intervention 5.4% and 17.1%; Quitline referral 4.4% and 18.8%; 
Usual GP care 2.9% and 16.4%. Only 43% of patients in the PN intervention group attended to 
see the nurse. Multilevel regression analysis showed no effect of the intervention overall, but 
patients who received partial or complete PN support were more likely to report sustained 
abstinence (partial support OR 2.27; complete support OR 5.34) .  
 
Conclusion  
The results show no difference by group on intention to treat analysis. Those patients who 
attended for follow-up and received more intensive PN intervention were more likely to quit. 
This may have been related to patient motivation or an effect of PN led cessation support. 
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Tobacco is the most common preventable cause of death in the world today. The World Health 
Organization estimates that tobacco killed 5.4 million people globally in 2008 and on current 
trends this will rise to 8 million deaths per year by 2030. (1) Despite the decrease in prevalence 
in tobacco use in developed countries it remains a major cause of preventable disease and death.  
The importance of promoting cessation of tobacco use and provision of treatment as part of a 
comprehensive approach to tobacco control is described in Article 14 in the Framework 
Convention for Tobacco Control but progress on providing services is variable across signatory 
countries. (2) 
 
General practice is well positioned to assist in smoking cessation support given the high degree 
of contact with the population. There is evidence that brief advice from a physician has a small 
effect (3) and that this can be increased substantially if combined with other evidence based 
support such as pharmacotherapy. Clinical practice guidelines suggest general practitioners 
(GPs) should identify smokers and offer cessation support at every opportunity, however there is 
a range of barriers to routinely providing smoking cessation advice and several studies have 
found the number of patients who report receiving advice from GPs is low. (4-6) 
 
An alternative to support in general practice is for GPs to identify smokers and refer to other 
services such as telephone Quitlines or specialist smoking cessation services. In an Australian 
study, which compared usual care by the GP to referral by the GP to the Quitline, a higher rate of 
sustained abstinence at three months follow-up was found in the referral group but there was no 
significant difference at 12 months. (7) In the United Kingdom, GPs are encouraged to identify 
smokers and refer to specialised tobacco treatment services. Overall service data has shown good 
short term quit rates but there is considerable local variation across services in throughput, 
success rates and impact. (8) In Australia, though there are a small number of smoking cessation 
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clinics and an increasing number of clinicians with specialised skills, there is no similar 
organised nationwide service. 
 
A model of enhanced cessation support within the practice is provision of advice by practice 
nurses (PN). The PN workforce in many countries is increasing and nurses have the potential to 
overcome barriers to providing smoking cessation support in general practice. (9) Nurse-led 
smoking cessation advice can be effective (10) but trials in general practice have shown variable 
results. (11-14) There were a range of limitations in these studies including low uptake of the 
nursing intervention, research designs that involved a one-off consultation and problems with 
retention of smokers in the study. (15) We conducted a before-after demonstration study of PN-
delivered smoking cessation advice in 19 practices in Sydney involving 398 smokers. The results 
were promising with continuous abstinence from quit day of 16% at six month follow-up and 
positive qualitative feedback from PNs and GPs on the value and feasibility of the nurse role. 
(16)   
 
In the current cluster randomised trial we evaluated the uptake and effectiveness of a flexible 
package of smoking cessation support provided primarily within the practice by the PN and 
tailored to meet the needs of patients. The intervention was based on the 5As approach (Ask, 
Assess, Advise, Assist Arrange follow-up), which provides a structure for comprehensive 
smoking cessation support in primary care. (17) This intervention was compared to Quitline 





A three arm cluster randomised trial, with randomisation at the level of the practice, was 
conducted. Details of the study protocol have been published. (18) Recruitment started in August 






General Practices located in Sydney and Melbourne employing at least one PN were identified 
with assistance from local general practice organisations and the Australian Practice Nurses 
Association and invited to participate. Interested GPs and PNs were visited by study staff to 
explain the study and obtain informed consent.  
 
Patients were approached in the waiting room of participating practices by trained research 
assistants over a two-week period and assessed for eligibility. Patients were potentially eligible if 
they were aged 18 years and over and either daily or weekly smokers. Individuals who were 
pregnant, unable to give informed consent or had insufficient English to participate were 
excluded. The study was explained to eligible patients and they were invited to participate. 
Baseline information on demographics, smoking status, nicotine dependence and co-morbidities 
was collected and patients were given a card indicating their enrolment and the allocation group 
of the practice to take into the GP consultation. In the Quit with PN practices, a copy of this card 
was provided to the PN and GPs encouraged patients to make an initial appointment to see the 
PN. De-identified data on age, gender and residential postcode were collected from those who 
declined to participate. 
 
Randomisation 
Randomisation of practices was performed after practice recruitment but prior to patient 
recruitment with allocation concealment by a researcher who took no further part in the study.  
 
Interventions 
Quit with Practice Nurse 
Details of the interventions have been previously published. In brief, nurses had attended a one-
day training program where they were educated in the 5As approach to smoking cessation 
counselling. (17) This approach forms the basis of clinical practice guidelines in Australia and a 
number of other countries and its effectiveness is supported by evidence from a randomised trial. 
(19) It can be provided in primary care and does not depend on referral to specialised services. 
Checklists for use by the nurses at each patient visit were provided as well as “Quit kits” (a 
printed resource used by Quitlines nationally) for distribution to patients. Nurses were supported 
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in providing the intervention by three pro-active mentoring telephone calls from an experienced 
smoking cessation counsellor. 
 
In the intervention model, GPs from practices randomised to the Quit with PN group encouraged 
all smokers to see the PN. At an assessment visit patients were assisted by PNs to develop a quit 
plan based on the 5As approach. (17) Patients were offered a flexible package of ongoing 
support with a further three face-to-face visits to the PN encouraged but telephone support from 
the nurse or the Quitline offered for patients unable to attend for face-to-face consultations or 
who preferred telephone counselling. PNs were asked to follow-up by telephone patients who 
failed to make an initial assessment visit. The practice received payment for the PN time in 
delivering the intervention at the rate of $30 per visit. 
 
Quitline referral 
In practices allocated to the Quitline referral group GPs were asked to assess the patients’ 
willingness to quit, and to offer brief advice. Patients with interest in quitting were offered 
referral to the Quitline and, if patients agreed, GP completed a fax referral form to Quitline. (17) 
On receiving a GP referral the Quitline telephoned the patient to offer services to meet their 
needs. Patients expressing interest in quitting and willing to engage with the Quitline counselling 
service were offered a series of free evidence-based proactive call back counselling/advice 
sessions. (20) The GP was provided brief feedback from the Quitline on uptake and outcomes of 
services offered.  
 
Control – usual care  
In control group practices the GPs were asked to assess patients’ willingness to quit and offer 
assistance in accordance with their usual practice. This could include advice within the practice, 
referral to Quitline or both, but no provision was made to facilitate either. 
 
Smoking cessation pharmacotherapy 
The need for smoking cessation pharmacotherapy was assessed by the GP or PN and offered in 
all three groups according to clinical practice guidelines. A copy of these guidelines was 
provided to participating GPs and PNs. (17) Patients in all groups who held a pharmaceutical 
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concession card and who were assessed as nicotine dependent and suitable for nicotine patches 
were eligible for free patches for a period of eight weeks. Other pharmacotherapies were either 
prescribed by the GP (bupropion or varenicline) or purchased by the patient over the counter 
(other forms of nicotine replacement therapy).  
 
Outcome measures 
Measures were performed at baseline and three and 12 months after recruitment. The three and 
12 month outcomes were collected via Computer Assisted Telephone Interviews (CATI) by 
trained research assistants who were blind to group allocation. The primary outcome measures 
were sustained abstinence ( ≥ one month at the three month follow up point and  ≥ 10 months at 
the 12 month follow-up) and point prevalence abstinence (≥ seven days sustained abstinence at 
the three month and 12 month  follow-up points). In line with guidance from the Society for 
Research on Nicotine and Tobacco validation of smoking cessation was not performed.(21) 
Uptake of the intervention was also measured in each group.  
 
Analysis 
We analysed the data by intention to treat. This analysis involved planned imputation where 
patients with missing outcome data were assumed to be smokers. This conservative imputation is 
common in smoking cessation studies. (22) We also conducted a planned analysis of outcomes 
for patients with complete outcome data. Given the incomplete uptake of interventions 
experienced in the trial we conducted an additional analysis of the outcomes for patients who had 
received the intervention versus not received. In the univariate analyses differences between 
groups were compared using the χ2 test statistic. In the other analyses multilevel logistic 
regression models were used with two dichotomous dependent variables adjusted for clustering 
of three occasions at level 1, patients at level 2 and practices at level 3. We conducted multilevel 
multivariable analysis using MLwiN. (23) Time is defined as the number of months from 
baseline and treated as a continuous variable. The significance of the parameter estimates was 
assessed using the Wald joint χ2 test statistic. The intracluster correlation co-efficients (ICC) for 






The study was powered to detect a between group differences at 12 months  in sustained 
abstinence of 5.5% between Quit with PN intervention versus the referral intervention and a 
9.4% difference between Quit with PN intervention and the usual care control group with 80% 
power at the 5% significance level. Adjustment for clustering was made on the basis of the ICC 
of 0.013 observed by Lennox et al. in a smoking cessation trial in general practice. (25) We 
planned to recruit 90 clusters with a cluster size of 25. The resulting sample size of 2250 allowed 
for an 18% loss of patients to follow-up.   
 
Results 
In total, 323 GPs and 135 PNs from 101 practices in Sydney and Melbourne participated in the 
study. Fifteen (14.9%) were solo practices. The mean age of the GPs was 49.5 years (SD 11.3) 
and 189 (59.4%) were male. The mean age of PNs was 50.0 years (SD 9.9) and 129 (95.6%) 
were female. The research assistants identified 3676 eligible patients of whom 2390 (65.0%) 
agreed to participate. Those who declined were more likely to be male (53.2%) (P < 0.001) but 
there were no differences between those who agreed and declined to participate in mean age or in 
socioeconomic status as determined by socio-economic indexes for areas (26) classification of 
the residential postcode. As shown in table 1 the groups were very similar on demographics and 
smoking behavior at baseline. As shown in the CONSORT diagram (figure1), 2282 (95.5%) 
completed the three month follow up and 1969 (82.4%) provided outcome data at the 12-month 
follow-up giving an attrition rate at 12 months of 17.6%.  Retention was 81.7% in the Quit with 
PN, 83.1% in the Quitline referral and 82.3% in the GP usual care groups.   
 
Intervention uptake across groups was assessed from patient report of contacts for smoking 
cessation collected by CATI. Uptake was low across all three groups. In the Quit with PN group, 
502 (57.3%) received no support from the PN (no visits), 140 (16%) received partial support 
(one or two visits), 148 (16.9%) received complete support (three or more visits) and 86 (9.8%) 
had missing data. In the Quitline referral group 588 (70%) had no support from the Quitline (no 
calls), 36 (4.3%) had partial support (one to three calls), 25 (3%) had complete support (four or 
more calls) and 187 (22.4%) had missing data. In the GP usual care group 310 (45.7%) had no 
support ( no follow-up visits where smoking was discussed), 193 (28.5%) had partial support 
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(one to two visits where smoking was discussed), 95 (14%) had complete support ( three or more 
visits where smoking was discussed) and 80 (11.8%) had missing data.  
 
Smoking cessation pharmacotherapy use was similar across intervention groups with 413 
(49.3%) patients in the Quit with PN group, 422 (53.2%) in the Quitline referral group and 282 
(43.3%) in the usual GP care group using one or more forms pharmacotherapy in the study 
period. Nicotine patches were the most commonly used form of pharmacotherapy, used by 284 
(33.9%) patients in the Quit with PN group, 299 (37.8%) in the Quitline referral group, 170 
(26.0%) in the GP usual care group and 753 (33.0%) in the whole study population. Of these 753 
patch users, 534 (70.1%) were pharmaceutical concession card holders and 219 (29.1%) were 
not. This suggests that some patients who were not concession card holders were supplied with 
free nicotine patches. Uptake of varenicline was similar across groups with 121 (13.8%) of 
patients in the Quit with PN group, 123 (14.7%) in the Quitline referral and 89 (13.1%) in the GP 
usual care group using this medicine in the study period. Only 18 patients in the study used 
bupropion.  
 
The unadjusted univariate results of the intention to treat analysis are shown in table 2.  Though 
sustained abstinence was higher in the Quit with PN group at 12 months there were no 
statistically significant between group differences for the primary outcome measures of sustained 
and point relevance abstinence at three months or 12 months. The sustained and point prevalence 
abstinence rates respectively at three months by group were: PN intervention 13.7% and 17.1%; 
Quitline referral 11.4% and 15.0%; Usual GP care 11.8% and 15.6%. At 12 months the rates 
were: PN intervention 6.6% and 20.9%; Quitline referral 5.3% and 22.6%; Usual GP care 3.6% 
and 19.9%. The differences were not statistically significant. Given that multilevel analysis with 
adjustment for clustering will decrease the effect size and increase P values our statistician (UJ) 
did not conduct these analyses.(27, 28) The univariate analysis of results for patients with 
complete outcome data showed similar results. 
 
 As shown in figure 2 there were higher quit rates in patients in the Quit with PN group who had 
attended for smoking cessation support visits with the PN. A multilevel adherence analysis was 
conducted which examined outcomes for all patients who had received versus not received 
10 
 
intervention (Table 3). Independent variables were included in the model describing the extent of 
intervention received in all three groups. The variable of partial PN support (defined as one or 
two visits) and complete PN support or complete PN intervention received (defined as three or 
more visits) were significantly associated with higher rates of sustained and point prevalence 
abstinence.  Complete PN support associated with higher odds ratios for both point prevalence 
and sustained abstinence than partial PN support. The extent of GP support received was also 
associated with cessation, though a dose response effect was not observed. Given the small 
numbers of patients had received Quitline assistance the categories were collapsed to one or 
more call versus no support. Receiving one or more call was not associated with higher 
likelihood of cessation.  
 
Finally a multilevel regression model included variables related to practice size, patient 
demographics, smoking history and co-morbidities (Table 4). Patient characteristics of older age, 
previous quit attempts, low nicotine dependence, use of smoking cessation pharmacotherapy in 
the study period, absence of a mental health problems and absence of co-morbid conditions were 




Despite successful participant recruitment and retention, this large cluster randomised trial found 
no difference in the primary outcomes between intervention groups. As we exceeded our 
recruitment target for the study we do not believe this was due to a type 2 error. A reason for the 
lack of effect shown may have been the low uptake of the PN and Quitline referral interventions. 
Only 43% of patients in Quit with PN practices saw the nurse one or more times while in the 
Quitline referral practices only 30% had one or more contact with the Quitline. The low uptake 
of the Quitline may have been due to referrals not being made by GPs despite being randomised 
to that intervention group or a lack of acceptance by patients. Further, there appears to have been 
more than usual support within practices in the GP usual care group. Although the nature of the 





Comparison with other research 
Low intervention uptake has been found in other studies of practice nurse cessation support. (11, 
29) In our study the low uptake may have been related to the recruitment method in that patients 
were offered the intervention opportunistically when they attended the practice for any reason. 
This represents the approach suggested in clinical practice guidelines where smokers are 
identified and offered cessation support at every opportunity. (30) However it is likely to result 
in a higher proportion of less motivated patients entering the study compared to more targeted 
recruitment methods such as a mailed out invitation or the GP selecting interested patients. This 
may explain the differences in outcomes in the trial compared with our earlier before-after study 
(16) in which GPs identified interested and motivated patients and referred them to the practice 
nurse for recruitment and intervention. As was found in the study by Sanders et al (29) and also 
noted in other cardiovascular risk factor  interventions by PNs, those patients who attended to see 
the PN were more likely to report behaviour change. (15). In our study this was even the case 
with one PN visit but the cessation rate was greater with increasing intervention intensity, 
suggesting a dose-response effect. However the effect may be simply due to more motivated 
patients remaining in treatment.  The low rate of completion of the nurse visits may have been 
related to PNs experiencing difficulty in finding the time and organisational support to deliver 
the intervention as planned. This will be explored in the qualitative evaluation of the study. 
 
In the multilevel regression analysis a number of other independent variables were found to be 
significantly positively associated with smoking cessation. The strongest association was with 
use of pharmacotherapy during the study. This is consistent with the known benefits of treating 
nicotine dependence. (31)  The other positive associations for both point prevalence and 
sustained abstinence were: age 60 years and over, having tried to quit before and the patient’s 
self-rating that quitting would be fairly difficult or less. There was also a positive association for 
point prevalence abstinence with not having a mental health problem. These associations are 
consistent with previous literature (32, 33), including our qualitative study involving people 
reporting current depression at baseline in the Quit in General Practice Study (34) though there is 






There was a substantial level of participation in the study by eligible smokers (65%) but there 
was possible bias in recruitment in that more women were willing to participate than men. 
However this is in keeping with the higher attendance rates of women than men in general 
practice. We have limited information to report in this paper on the fidelity of the intervention 
provided in the study. Nurses in the Quit with PN practices were asked to use intervention 
checklists at each visit and to send these to the study team. The extent to which this was done 
and the content of these checklists will be reported separately. The information gathered in the 
process evaluation of the impact of the intervention is also beyond the scope of this paper and 
will be reported in subsequent publications. Biochemical validation of cessation outcomes was 
not practically possible in this large community-based study so there is the possibility that 
cessation rates are lower than those reported. However our approach is supported by a review of 
the evidence conducted by the Society for Research on Nicotine and Tobacco which concluded 
that in large trials recruited though health care settings misreporting rates are generally very low, 
typically near zero, except in high-risk medical settings, such as involving patients with heart 
disease or pregnant women. (21) We assumed that participants lost to follow-up had relapsed to 
smoking. This is commonly done in smoking cessation studies but could have led to an 
overestimation of the difference in quit rates from those who had received versus not received 
the PN intervention.   
 
Study implications 
The study that a PN delivered intervention was not effective when offered opportunistically to all 
smokers presenting in general practice. There was a suggestion however that PN led support may 
be effective if patients can be engaged and maintained in treatment. Given these findings, and the 
pressures on PN time, testing strategies to identify those patients with sufficient motivation to 
attend to see the nurse and offering them the nurse-led intervention may be both effective and 
efficient. Methods of doing this could be via an invitation to the practice population of recorded 
smokers, by the GP and/or PN assessing motivation and offering the service when patients who 
smoke attend for other reasons or by a combination of these methods. Further research, including 
cost-effectiveness analysis, is needed to evaluate such a nurse-led model of smoking cessation 
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Quitline referral: 836 
patients in 33 practices 
Mean cluster size 25.3 
Range (7 to 53 patients) 
1286 patients declined to 
take part 
2390 patients consented in 
101 practices 
Usual GP care: 678 
patients in 32 practices 
Mean cluster size 21.2 
Range (3 to 59 patients) 
Quit with PN: 876 patients  
in 36 practices  
Mean cluster size 24.3 
Range (3 to 62 patients) 
Quitline referral: 792 
patients in 33 practices 
Mean cluster size: 23.6 
Range (7 to 50 patients) 
Lost to follow up: 
Clusters: 0 
Patients: 44 
Dropped out: 13 
Not contactable: 28 
Deceased: 3 
Usual GP care 653 
patients in 32 practices 
Mean cluster size (20.1) 
Range (2 to 56 patients) 
Lost to follow up: 
Clusters: 0 
Patients 25 
Dropped out: 9 
Not contactable: 16 
Deceased: 0 
Quit with PN: 837  
patients in 36 practices 
Mean cluster size 23.4 
Range (3 to 61 patients) 
Lost to follow up 
Clusters: 0 
Patients: 39 
Dropped out: 15 
Not contactable: 24 
Deceased: 0d: 0 
Quit with PN: 716 patients 
In 36 practices 
Mean cluster size 19.9 
Range (3 to 52 patients) 
Lost to follow up 
Clusters: 0 
Patients: 121 
Dropped out: 59 
Not contactable: 59 
Deceased: 3 
Quitline referral: 695 
patients in 33 practices 
Mean cluster size: 21.1 
Range (5 to 42 patients) 
Lost to follow up 
Clusters: 0 
Patients: 97 
 Dropped out: 54 
Not contactable: 41 
Deceased: 2 
Usual GP care: 558 
patients in 32 practices 
Mean cluster size 17.4 
Range (3 to 44 patients) 
Lost to follow up 
Clusters: 0 
Patients: 95 
 Dropped out: 53 
Not contactable: 41 
Deceased: 1 























































Table 1 | Baseline characteristics of groups. N=2390. Data collected from August 2010 to XXXX 
Figures are means (SDs) unless otherwise stated 
 Quit with PN 
 (n = 876 ) 
Quitline 
(n = 836 ) 
Usual GP care 
(n = 678) 
Mean age in years (SD)  42.6 (14.4) 43.5 (14.3)  42.1 (15.2) 
Number (%) of men  398 (45.4)  378 (45.2)  320 (47.2) 
Number (%) born in Australia 458 (67.6) 587 (70.2) 603 (68.8) 
Number (%) English spoken at home 778 (88.8%) 773 (92.5%) 606 (89.4%) 
Number (%) reported Aboriginal or Torres Strait 
Islander heritage 
33 (3.8) 28 (3.3) 15 (2.2) 
Number (%) completed High School  599 (68.4) 565 (67.6) 482 (67.6) 
Number (%) holding pharmaceutical concession card 492 (56.2) 448 (53.6) 324 (47.8) 
Number (%) employed part or full time  402 (45.9) 385 (46.1) 355 (52.4) 
Number (%) reporting mental health problem 333 (38.0) 309 (37.0) 221 (32.6) 
Mean number (SD) of co-morbidities  1.3 (1.5)  1.2 (1.3)  1.0 (1.3) 
Mean number (SD) of cigarettes per day  18.0 (11.0)  17.4 (10.7) 15.9  (9.7) 
Mean heaviness of smoking index (SD) 2.6 (1.3)  2.4 (1.3)  2.4 (1.4) 
Number (%) reporting previous quit attempt  732 (83.6)  701 (83.9)  531(78.3) 
Number (%) rated quitting as fairly difficult or less  249 (28.4) 250 (29.9) 212 (31.3) 
Number (%) responded “no” to higher quit success 
with assistance 
50 (5.7) 76 (9.1) 89 (13.1) 
Number (%) responded “not sure” to higher quit 
success with assistance 
270 (30.8) 251 (30.0) 191 (28.2) 
Number (%) previously used smoking cessation 
pharmacotherapy 









Table 2 | Univariate analysis of primary outcomes at three months and 12 months 
Variable Quit with PN 
(n = 876) 
Quitline 
referral 
(n = 836) 
Usual GP 
care 






Sustained abstinence      
3 months 115 (13.1%) 90 (10.8%) 77 (11.4%) 2.47 0.29 
12 months 47 (5.4) 37 (4.4) 20 (2.9) 5.37 0.068 
Point prevalence      
3 months 143 (16.3) 119 (14.2) 102 (15.0) 1.47 0.48 



































Table 3 | Multilevel logistic regression analysis and adherence analysis. Effect of independent variables on 





Variables (reference variable or group) OR (95% CI) OR (95% CI) 
Groups and time effect 
Quit with PN group (usual GP care group) 0.86 (0.65 to 1.13) 0.99 (0.70 to 1.39) 
Quitline referral group (usual GP care group) 0.94 (0.71 to 1.24) 0.92 (0.65 to 1.31) 
Time 1.11 (1.09 to 1.13)‡ 0.98 (0.95 to 1.00) 
PN, GP and Quitline support effect 
Partial nurse support (no nurse support) 1.79 (1.3 to 2.47) ‡ 2.27 (1.49 to 3.45) ‡ 
Complete nurse support (no nurse support) 3.39 (2.41 to 4.78) ‡ 5.34 (3.51 to 8.14) ‡ 
Partial GP support (no GP support) 1.61 (1.29 to 2.00) ‡ 2.45 (1.81 to 3.32) ‡ 
Complete GP support (no GP support) 1.32 (0.98 to 1.79) 1.79 (1.19 to 2.70) ‡ 
Quitline support one call or more (no Quitline 
support) 
1.41 (0.85 to 2.32) 1.32 (0.67 to 2.62) 
ICC (intracluster or intrapractice correlation) 0.012 0.00 
 
Note:  ‡ P < 0.001 













Table 4: Multilevel logistic regression analysis for effect of patient and practice characteristics on primary 
outcomes (N=6714** of 7170)  




Variables (reference variable) OR (95% CI) OR (95% CI) 
Patient demographics effect 
Age in years 
40-59 (19-39) 0.96 (0.77 to 1.20) 1.13 (0.84 to 1.53) 
60 or more (19-39) 1.57 (1.12 to 2.21)† 1.90 (1.20 to 3.03) † 
Female sex (male sex) 0.85 (0.70 to 1.03) 0.74 (0.56 to 0.96) 
Home language other than English (English) 0.88 (0.61 to 1.25) 0.95 (0.59 to 1.53) 
Aboriginal or Torres Strait Islander (Other than aboriginal) 1.00 (0.56 to 1.76) 0.93 (0.41 to 2.09) 
Employment status* 
Employed (other employment) 1.06 (0.82 to 1.36)  1.07 (0.76 to 1.52) 
Retired/pensioner (other employment) 0.71 (0.51 to 0.98) 0.67 (0.43 to 1.04) 
At least high school completed (high school not completed) 1.20 (0.96 to 1.50) 1.12 (0.82 to 1.51) 
Pharmaceutical concession card holder (not pharmaceutical 
concession card holder) 
0.95 (0.75 to 1.20) 1.28 (0.93 to 1.77) 
Smoking history effect 
Tried to quit before (did not try to quit before) 1.50 (1.12 to 2.02) † 1.65 (1.07 to 2.53)* 
Rated quit difficulty fairly difficult or less (difficult or very 
difficult) 
1.56 (1.27 to 1.92) ‡ 1.45 (1.09 to 1.94)* 
Higher quit success with assistance 
Reported no (reported yes) 1.18 (0.84 to 1.67) 0.89 (0.54 to 1.48) 
Reported not sure (reported yes) 1.14 (0.92 to 1.41) 1.10 (0.82 to 1.48) 
Heaviness of smoking index 
Low dependence (high dependence) 3.10 (1.54 to 6.22) † 2.61 (1.05 to 6.47)* 
Medium dependence (high dependence) 1.71 (0.87 to 3.37) 1.41 (0.59 to 3.38) 
Used pharmacotherapy during study (did not use 
pharmacotherapy) 
5.85 (4.83 to 7.09) ‡ 5.78 (4.43 to 7.54) ‡ 
Comorbidities effect 
No mental health problem reported (reported mental health 
problem) 
1.34 (1.00 to 1.79)* 0.92 (0.61 to 1.38) 
Number of comorbid conditions   
23 
 
Zero (2 or more comorbidities) 1.25 (0.91 to 1.74) 1.88 (1.19 to 2.97) † 
One (2 or more comorbidities) 1.13 (0.85 to 1.49) 1.14 (0.77 to 1.68) 
Effect of practice size 
Solo practice (group practice) 1.04 (0.74 to 1.47) 1.30 (0.85 to 1.99) 
ICC (intracluster or intrapractice correlation) 0.020 0.019 
 
Note:  * P < 0.05, † P < 0.01; ‡ P < 0.001 
 ** number of practices = 101 
 
